JP2019116465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019116465A5 JP2019116465A5 JP2018211118A JP2018211118A JP2019116465A5 JP 2019116465 A5 JP2019116465 A5 JP 2019116465A5 JP 2018211118 A JP2018211118 A JP 2018211118A JP 2018211118 A JP2018211118 A JP 2018211118A JP 2019116465 A5 JP2019116465 A5 JP 2019116465A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methoxy
- pharmaceutical composition
- dihydro
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229960004316 cisplatin Drugs 0.000 claims 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 4-Methoxy-6-methyl-2-oxo-1,2-dihydro-pyridine-3-yl Chemical group 0.000 claims 5
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 claims 1
- RXCVUHMIWHRLDF-UHFFFAOYSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)C(C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-UHFFFAOYSA-N 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762585781P | 2017-11-14 | 2017-11-14 | |
| US62/585781 | 2017-11-14 | ||
| US201862628314P | 2018-02-09 | 2018-02-09 | |
| US62/628314 | 2018-02-09 | ||
| US201862684832P | 2018-06-14 | 2018-06-14 | |
| US62/684832 | 2018-06-14 | ||
| US201862739990P | 2018-10-02 | 2018-10-02 | |
| US62/739990 | 2018-10-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019116465A JP2019116465A (ja) | 2019-07-18 |
| JP2019116465A5 true JP2019116465A5 (enExample) | 2021-11-18 |
| JP7201400B2 JP7201400B2 (ja) | 2023-01-10 |
Family
ID=64453535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018211118A Active JP7201400B2 (ja) | 2017-11-14 | 2018-11-09 | Ｅｚｈ２阻害剤組合せ療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11529344B2 (enExample) |
| EP (1) | EP3710057A1 (enExample) |
| JP (1) | JP7201400B2 (enExample) |
| KR (1) | KR20200088386A (enExample) |
| CN (1) | CN111356478A (enExample) |
| AU (1) | AU2018369841A1 (enExample) |
| BR (1) | BR112020008325A2 (enExample) |
| CA (1) | CA3082287C (enExample) |
| IL (1) | IL274415A (enExample) |
| MX (1) | MX2020004731A (enExample) |
| RU (1) | RU2754131C1 (enExample) |
| SG (1) | SG11202003477QA (enExample) |
| TW (1) | TWI698238B (enExample) |
| WO (1) | WO2019097369A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| EP2566327B1 (en) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| KR101339500B1 (ko) | 2011-10-18 | 2013-12-09 | 경상대학교산학협력단 | 쌀벌레 방제용 소형 패치 및 젤 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| WO2014066532A1 (en) | 2012-10-23 | 2014-05-01 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| CA2926423C (en) | 2013-10-07 | 2022-05-24 | Google Inc. | Automated crowdsourced power outage identification and staggering of hvac system restarts |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| MY185765A (en) | 2014-06-17 | 2021-06-06 | Pfizer | Substituted dihydroisoquinolinone compounds |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| EP3407978A4 (en) * | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| US10987353B2 (en) * | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
| US20200024352A1 (en) | 2016-12-08 | 2020-01-23 | Eli Lilly And Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
-
2018
- 2018-11-09 CA CA3082287A patent/CA3082287C/en active Active
- 2018-11-09 TW TW107139825A patent/TWI698238B/zh not_active IP Right Cessation
- 2018-11-09 RU RU2020115715A patent/RU2754131C1/ru active
- 2018-11-09 EP EP18807711.9A patent/EP3710057A1/en not_active Withdrawn
- 2018-11-09 SG SG11202003477QA patent/SG11202003477QA/en unknown
- 2018-11-09 KR KR1020207016752A patent/KR20200088386A/ko not_active Withdrawn
- 2018-11-09 JP JP2018211118A patent/JP7201400B2/ja active Active
- 2018-11-09 WO PCT/IB2018/058795 patent/WO2019097369A1/en not_active Ceased
- 2018-11-09 MX MX2020004731A patent/MX2020004731A/es unknown
- 2018-11-09 BR BR112020008325-9A patent/BR112020008325A2/pt not_active Application Discontinuation
- 2018-11-09 US US16/762,388 patent/US11529344B2/en active Active
- 2018-11-09 CN CN201880073705.2A patent/CN111356478A/zh active Pending
- 2018-11-09 AU AU2018369841A patent/AU2018369841A1/en not_active Abandoned
-
2020
- 2020-05-04 IL IL274415A patent/IL274415A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113767106A (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 | |
| Wawruszak et al. | Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines–an isobolographic analysis | |
| JP2017504611A5 (enExample) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| Wang et al. | Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways | |
| JP2018529656A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2017178948A5 (enExample) | ||
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| JP2016518337A5 (enExample) | ||
| CN110139865A (zh) | Fgfr抑制剂 | |
| JP2016501221A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2016528162A5 (enExample) | ||
| JP2014532704A5 (enExample) | ||
| CN109689652A (zh) | 稠杂环类衍生物、其制备方法及其在医学上的应用 | |
| CN115315423A (zh) | 取代芳基类化合物 | |
| CN111566100A (zh) | 嘧啶类化合物、其制备方法及其医药用途 | |
| CN115135649A (zh) | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 | |
| JP2018521121A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016518370A5 (enExample) | ||
| TW202402290A (zh) | 癌症治療 | |
| Lee et al. | Antitumor activity of acriflavine in lung adenocarcinoma cell line A549 | |
| CN114072404A (zh) | Ret选择性抑制剂及其制备方法和用途 |